• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺纤维化合并肺气肿综合征患者的肺动脉高压。

Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.

机构信息

Hospices civils de Lyon, Hôpital Louis Pradel, Service de pneumologie - Centre de référence des maladies pulmonaires rares, Université de Lyon, Université Lyon I, UCBL-INRA-ENVL-EPHE, UMR754, IFR128, Lyon, France.

出版信息

Eur Respir J. 2010 Jan;35(1):105-11. doi: 10.1183/09031936.00038709. Epub 2009 Jul 30.

DOI:10.1183/09031936.00038709
PMID:19643948
Abstract

This study aims to describe the haemodynamic and survival characteristics of patients with pulmonary hypertension in the recently individualised syndrome of combined pulmonary fibrosis and emphysema. A retrospective multicentre study was conducted in 40 patients (38 males; age 68+/-9 yrs; 39 smokers) with combined pulmonary fibrosis and emphysema, and pulmonary hypertension at right heart catheterisation. Dyspnoea was functional class II in 15%, III in 55% and IV in 30%. 6-min walk distance was 244+/-126 m. Forced vital capacity was 86+/-18%, forced expiratory volume in 1 s 78+/-19%, and carbon monoxide diffusion transfer coefficient 28+/-16% of predicted. Room air arterial oxygen tension was 7.5+/-1.6 kPa (56+/-12 mmHg). Mean pulmonary artery pressure was 40+/-9 mmHg, cardiac index 2.5+/-0.7 L x min(-1) x m(-2) and pulmonary vascular resistance 521+/-205 dyn x s x cm(-5). 1-yr survival was 60%. Higher pulmonary vascular resistance, higher heart rate, lower cardiac index and lower carbon monoxide diffusion transfer were associated with shorter survival. Patients with combined pulmonary fibrosis and emphysema syndrome and pulmonary hypertension confirmed by right heart catheterisation have a dismal prognosis despite moderately altered lung volumes and flows and moderately severe haemodynamic parameters.

摘要

这项研究旨在描述特发性肺纤维化合并肺气肿(CPFE)患者合并肺动脉高压的血流动力学和生存特征。在 40 名 CPFE 合并肺动脉高压的患者(38 名男性;年龄 68+/-9 岁;39 名吸烟者)中进行了一项回顾性多中心研究。右心导管检查显示,呼吸困难为 II 级(15%)、III 级(55%)和 IV 级(30%)。6 分钟步行距离为 244+/-126m。用力肺活量为 86+/-18%,1 秒用力呼气量为 78+/-19%,一氧化碳弥散转移系数为预测值的 28+/-16%。空气动脉血氧分压为 7.5+/-1.6 kPa(56+/-12 mmHg)。平均肺动脉压为 40+/-9 mmHg,心指数为 2.5+/-0.7 L x min(-1) x m(-2),肺血管阻力为 521+/-205 dyn x s x cm(-5)。1 年生存率为 60%。较高的肺血管阻力、较高的心率、较低的心指数和较低的一氧化碳弥散转移与较短的生存时间相关。尽管肺容积和流量中度改变,血流动力学参数中度严重,但经右心导管检查证实的 CPFE 合并肺动脉高压患者预后不佳。

相似文献

1
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.肺纤维化合并肺气肿综合征患者的肺动脉高压。
Eur Respir J. 2010 Jan;35(1):105-11. doi: 10.1183/09031936.00038709. Epub 2009 Jul 30.
2
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity.合并性肺纤维化和肺气肿:一种未被充分认识的独特病症。
Eur Respir J. 2005 Oct;26(4):586-93. doi: 10.1183/09031936.05.00021005.
3
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.淋巴管肌瘤病相关肺动脉高压:20 例患者的特征。
Eur Respir J. 2012 Sep;40(3):630-40. doi: 10.1183/09031936.00093111. Epub 2012 Feb 23.
4
[Pulmonary fibrosis and emphysema].[肺纤维化与肺气肿]
Rev Med Suisse. 2011 Apr 13;7(290):808, 810-2.
5
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.结节病相关的肺动脉高压:机制、血流动力学及预后
Thorax. 2006 Jan;61(1):68-74. doi: 10.1136/thx.2005.042838. Epub 2005 Oct 14.
6
Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease.结缔组织病合并肺纤维化和肺气肿综合征
Arthritis Rheum. 2011 Jan;63(1):295-304. doi: 10.1002/art.30077.
7
[Combined pulmonary fibrosis and emphysema syndrome].[合并性肺纤维化和肺气肿综合征]
Lijec Vjesn. 2015 Jan-Feb;137(1-2):22-6.
8
Vascular and cardiac reactivity in pulmonary hypertension due to chronic obstructive lung disease: assessment with various oxygen concentrations.慢性阻塞性肺疾病所致肺动脉高压中的血管和心脏反应性:不同氧浓度下的评估
Eur Respir J. 1992 May;5(5):525-30.
9
[Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].吸入性前列环素和伊洛前列素治疗继发于肺纤维化的重度肺动脉高压
Pneumologie. 2000 Mar;54(3):133-42. doi: 10.1055/s-2000-9076.
10
[Combined pulmonary fibrosis and emphysema syndrome].[合并性肺纤维化和肺气肿综合征]
Zhonghua Jie He He Hu Xi Za Zhi. 2010 Jul;33(7):515-8.

引用本文的文献

1
Incidence of primary graft dysfunction and its associated risk factors after lung transplantation: a systematic review and meta-analysis.肺移植术后原发性移植物功能障碍的发生率及其相关危险因素:一项系统评价和荟萃分析。
Surg Today. 2025 Sep 17. doi: 10.1007/s00595-025-03129-4.
2
Classification and course of pulmonary hypertension associated with end-stage COPD.终末期慢性阻塞性肺疾病相关肺动脉高压的分类与病程
ERJ Open Res. 2025 Jul 21;11(4). doi: 10.1183/23120541.01141-2024. eCollection 2025 Jul.
3
Comorbidities' Effect on IPF: Pathogenesis and Management.
合并症对特发性肺纤维化的影响:发病机制与管理
Biomedicines. 2025 Jun 1;13(6):1362. doi: 10.3390/biomedicines13061362.
4
Targeting USP11 counteracts -associated interstitial lung disease in hiPSCs-derived alveolar organoids and in vivo models.靶向USP11可对抗人诱导多能干细胞衍生的肺泡类器官和体内模型中的特发性肺间质疾病。
Theranostics. 2025 Mar 19;15(10):4526-4549. doi: 10.7150/thno.105994. eCollection 2025.
5
The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis.合并症对特发性肺纤维化患者抗纤维化治疗中断的影响。
Pharmaceuticals (Basel). 2025 Mar 14;18(3):411. doi: 10.3390/ph18030411.
6
Exercise-induced Right-to-left Shunt in a Patient with Combined Pulmonary Fibrosis and Emphysema.合并肺纤维化和肺气肿患者运动诱发的右向左分流
Intern Med. 2025;64(6):899-903. doi: 10.2169/internalmedicine.3753-24. Epub 2025 Mar 15.
7
Respiratory Pathology and Cardiovascular Diseases: A Scoping Review.呼吸病理学与心血管疾病:一项范围综述
Open Respir Arch. 2024 Nov 23;7(1):100392. doi: 10.1016/j.opresp.2024.100392. eCollection 2025 Jan-Mar.
8
Combined pulmonary fibrosis and emphysema and lung transplantation: current evidence and future directions.合并性肺纤维化和肺气肿与肺移植:当前证据及未来方向
J Thorac Dis. 2024 Nov 30;16(11):7290-7299. doi: 10.21037/jtd-24-1200. Epub 2024 Nov 21.
9
Transplantation, bridging, and support technologies in pulmonary hypertension.肺动脉高压的移植、桥接和支持技术。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01193-2024. Print 2024 Oct.
10
Effectiveness of upfront triple oral combination therapy with additional pirfenidone in a patient with severe pulmonary hypertension associated with lung diseases.在一名患有与肺部疾病相关的重度肺动脉高压患者中,联用吡非尼酮的初始三联口服联合疗法的疗效。
Respirol Case Rep. 2024 Aug 26;12(8):e70010. doi: 10.1002/rcr2.70010. eCollection 2024 Aug.